Haruko Daga

2.9k total citations
92 papers, 911 citations indexed

About

Haruko Daga is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Haruko Daga has authored 92 papers receiving a total of 911 indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Pulmonary and Respiratory Medicine, 66 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Haruko Daga's work include Lung Cancer Treatments and Mutations (62 papers), Lung Cancer Research Studies (32 papers) and Lung Cancer Diagnosis and Treatment (25 papers). Haruko Daga is often cited by papers focused on Lung Cancer Treatments and Mutations (62 papers), Lung Cancer Research Studies (32 papers) and Lung Cancer Diagnosis and Treatment (25 papers). Haruko Daga collaborates with scholars based in Japan, United States and Greece. Haruko Daga's co-authors include Nobuyuki Yamamoto, Kazuhiko Nakagawa, Isamu Okamoto, Shunichi Sugawara, Takashi Seto, Kōichi Goto, Toshiaki Takahashi, Haruyasu Murakami, Hidetoshi Hayashi and Kazumi Nishino and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Haruko Daga

82 papers receiving 897 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Haruko Daga Japan	16	611	594	182	181	96	92	911
Daniel Lee South Korea	12	631 1.0×	519 0.9×	100 0.5×	197 1.1×	101 1.1×	35	850
Bo Jin China	17	703 1.2×	527 0.9×	147 0.8×	202 1.1×	45 0.5×	71	972
Reyes Bernabé Spain	19	611 1.0×	684 1.2×	173 1.0×	211 1.2×	89 0.9×	92	1.1k
Fausto Barbieri Italy	22	780 1.3×	757 1.3×	156 0.9×	216 1.2×	112 1.2×	64	1.2k
Kuniko Sunami Japan	16	297 0.5×	320 0.5×	196 1.1×	150 0.8×	46 0.5×	47	638
Jose M. Pacheco United States	16	485 0.8×	591 1.0×	148 0.8×	196 1.1×	97 1.0×	39	800
Claudio Dazzi Italy	17	494 0.8×	556 0.9×	211 1.2×	220 1.2×	179 1.9×	57	982
Francis Parnis Australia	14	457 0.7×	328 0.6×	160 0.9×	186 1.0×	41 0.4×	60	761
Liming Sheng China	15	273 0.4×	480 0.8×	146 0.8×	165 0.9×	79 0.8×	44	784
D. H. Lee South Korea	12	670 1.1×	537 0.9×	120 0.7×	164 0.9×	94 1.0×	15	880

Countries citing papers authored by Haruko Daga

Since Specialization

Citations

This map shows the geographic impact of Haruko Daga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haruko Daga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haruko Daga more than expected).

Fields of papers citing papers by Haruko Daga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haruko Daga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haruko Daga. The network helps show where Haruko Daga may publish in the future.

Co-authorship network of co-authors of Haruko Daga

This figure shows the co-authorship network connecting the top 25 collaborators of Haruko Daga. A scholar is included among the top collaborators of Haruko Daga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haruko Daga. Haruko Daga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Akamatsu, Hiroaki, Toshihiro Misumi, Tadashi Aoki, et al.. (2025). Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies. Lung Cancer. 201. 108437–108437.

Kogure, Yoshihito, Hiroya Hashimoto, Haruko Daga, et al.. (2024). Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%. JTO Clinical and Research Reports. 6(3). 100784–100784.

Niho, Seiji, Yasuhiro Gotô, Haruko Daga, et al.. (2024). Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study. ESMO Open. 9(8). 103642–103642. 2 indexed citations

Yoh, Kiyotaka, Yoshitaka Zenke, Shingo Kitagawa, et al.. (2023). 1276P Genomic screening by multi-gene assay for perioperative targeted therapy in patients with early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD. Annals of Oncology. 34. S737–S737. 1 indexed citations

Zenke, Yoshitaka, Kiyotaka Yoh, Shingo Kitagawa, et al.. (2023). 1282P Concordance of PD-L1 expression between biopsy and matched surgical specimen in early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD. Annals of Oncology. 34. S740–S741. 1 indexed citations

Shiraishi, Yoshimasa, Takayuki Shimose, Hidenobu Ishii, et al.. (2022). Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases. Cancer Management and Research. Volume 14. 3449–3453. 3 indexed citations

O’Byrne, Kenneth J., Makoto Nishio, Hiroshi Sakai, et al.. (2022). First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients. ESMO Open. 7(1). 100394–100394. 14 indexed citations

Morise, Masahiro, Hiroshi Sakai, Terufumi Kato, et al.. (2021). MO19-2 INSIGHT2: Tepotinib + osimertinib in pts with EGFR-mutant NSCLC and acquired resistance to 1L osimertinib due to METamp. Annals of Oncology. 32. S309–S309.

Tachihara, Motoko, Kayoko Tsujino, Takeaki Ishihara, et al.. (2021). Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L). Cancer Management and Research. Volume 13. 9167–9173. 5 indexed citations

10.

Hayashi, Hidetoshi, Kimio Yonesaka, Shunichi Sugawara, et al.. (2021). FP14.16 Phase 2 Trial of the Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer (WJOG10818L/Alt Trial). Journal of Thoracic Oncology. 16(3). S234–S235. 1 indexed citations

11.

Kaneda, Hiroyasu, Kenji Sawa, Haruko Daga, et al.. (2021). Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases. Investigational New Drugs. 39(6). 1598–1603. 3 indexed citations

12.

Watanabe, Satomi, Takeharu Yamanaka, Kentaro Ito, et al.. (2019). OA02.06 The Sequential Therapy of Crizotinib Followed by Alectinib: Real World Data of 840 Patients with NSCLC Harboring ALK-Rearrangement (WJOG9516L). Journal of Thoracic Oncology. 14(10). S209–S210. 1 indexed citations

13.

Takeda, Koji, Haruko Daga, & Rieko Nakamura. (2016). Team management for skin toxicity induced by afatinib. Annals of Oncology. 27. vii39–vii39.

14.

Shukuya, Takehito, Takeharu Yamanaka, Takashi Seto, et al.. (2015). Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. The Lancet Oncology. 16(16). 1630–1638. 65 indexed citations

15.

Tamiya, Motohiro, Akihiro Tamiya, Hiroyasu Kaneda, et al.. (2015). A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer. Medical Oncology. 33(1). 2–2. 12 indexed citations

16.

Takeda, Kazuya, Hiroko Fukushima, Toru Inoue, et al.. (2014). A Case Report of Epithelioid Inflammatory Myofibroblastic Sarcoma with RANBP2-ALK Fusion Gene Treated with the ALK Inhibitor, Crizotinib. Japanese Journal of Clinical Oncology. 44(9). 868–871. 50 indexed citations

17.

Okamoto, Isamu, Masayuki Takeda, Haruko Daga, et al.. (2013). Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. Cancer Chemotherapy and Pharmacology. 71(4). 859–865. 7 indexed citations

18.

Tamiya, Motohiro, Shinya Tokunaga, Hidekazu Suzuki, et al.. (2012). Prospective Study of Urinary and Serum Cross-Linked N-Telopeptide of Type I Collagen (NTx) for Diagnosis of Bone Metastasis in Patients With Lung Cancer. Clinical Lung Cancer. 14(4). 364–369. 16 indexed citations

19.

Okamoto, Isamu, Koji Takeda, Haruko Daga, et al.. (2010). Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. Lung Cancer. 70(2). 168–173. 8 indexed citations

20.

Ohashi, Nobuyuki, et al.. (2004). Phase I/II Study of Carboplatin and Weekly Paclitaxel for Advanced Non-Small Cell Lung Cancer. Haigan. 44(2). 77–82.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact